June 13, 2025
2 min watch
Key takeaways:
- Coronary heart in Diabetes brings collectively leaders within the fields of cardiology, endocrinology, nephrology and extra.
- Takeaways from this 12 months’s assembly embody drugs for hypertension and hypercortisolism.
PHILADELPHIA — Hypertension remedy and the position of cortisol in cardio-renal-metabolic well being have been among the many featured matters from this 12 months’s Coronary heart in Diabetes CME Convention, in response to Richard E. Pratley, MD.
Pratley, the Samuel E. Crockett Chair in Diabetes Analysis, medical director of AdventHealth Diabetes Institute and a Healio | Endocrine As we speak Co-editor, mentioned this 12 months’s convention emphasised how cardiac, endocrine and renal situations intertwine and centered on methods well being care skilled can enhance scientific outcomes for his or her sufferers. On the conclusion of the assembly, Pratley shared with Healio his three key takeaways.
Editor’s be aware: Watch the Healio Unique video interview beneath.
A ‘resurgence’ of curiosity in hypertension
Pratley mentioned there was a big give attention to hypertension. A session introduced Jan Basile, MD, professor of drugs within the division of cardiology at Medical College of South Carolina and the Ralph H. Johnson VA Medical Middle in Charleston, South Carolina, centered on aldosteronism in folks with hypertension and the way aldosterone dysregulation performs a big half within the pathogenesis of hypertension and different cardiometabolic issues. Basile additionally examined a number of lessons of medicines that might be used to handle sufferers with aldosteronism and hypertension sooner or later.
“I believe there’s going to be some new curiosity in methods to handle hypertension,” Pratley mentioned. “There’s lots of discuss learn how to handle [use of] mineralocorticoid receptor antagonists, aldosteronism synthase inhibitors and renin-angiotensin-system blockers in hypertension.”
How hypercortisolism drives cardiometabolic illnesses
This 12 months’s assembly featured a session devoted to cortisol and the way it interacts with cardio-renal-metabolic illnesses.
As Healio beforehand reported, findings from half one of many CATALYST trial discovered 24% of adults with difficult-to-treat kind 2 diabetes have hypercortisolism. These with hypercortisolism have been invited to take part in half two of the trial, the place these randomly assigned to obtain mifepristone (Korlym, Corcept Therapeutics) had a 1.32 share level higher discount in HbA1c at 24 weeks in contrast with adults assigned placebo.
The Coronary heart in Diabetes session offered a deep dive of the CATALYST findings and examined the remedy of hypertension, dyslipidemia and different cardiac abnormalities for folks with hypercortisolism, in addition to properly as how cortisol could affect kidney operate.
“That is one other space the place there’s going to be continued development sooner or later,” Pratley mentioned.
Pioneers in cardiometabolic analysis
Pratley mentioned one in every of his favourite talks from the convention was the Luminary in Cardiometabolic Drugs Award lecture given by this 12 months’s recipient, Darren Okay. McGuire, MD, MHSc, the Jere H. Mitchell, MD Distinguished Chair in Cardiovascular Science and a distinguished instructing professor of drugs at College of Texas Southwestern Medical Middle. Pratley mentioned McGuire’s analysis has had a “noticeable” affect on sufferers.
Pratley additionally highlighted a lecture by former FDA commissioner Robert M. Califf, MD. Califf spoke about the necessity to leverage digital well being expertise and first care to enhance the well being system within the U.S.
For extra data:
Richard E. Pratley, MD, may be reached at richard.pratley.md@adventhealth.com.
Sources/Disclosures
Collapse
Healio Interviews
Disclosures:
Pratley reviews talking for Eli Lilly and Novo Nordisk; consulting for AbbVie, Altanine, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Eli Lilly, Endogenex, F. Hoffman-La Roche, Gasherbrum Bio, Genprex, Getz Pharma, Hanmi Pharmaceutical, Intas Prescribed drugs, Lexicon, Novo Nordisk, Pfizer, Regeneron, Scholar Rock and Solar Prescribed drugs; and receiving analysis grants from Biomea Fusion, Carmot Therapeutics, Dompe, Eli Lilly, Endogenex, Fractyl, Novo Nordisk and Sanofi.
